Mukund mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

KILITCH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+4.0%1-day move

₹176.50

prior close

₹176.04

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.1+1.3+1.4+1.6+4.0+3.6+4.8+2.2+2.6+2.0+2.2+7.6+0.3—

Up moveDown movePending

AI summary

Mukund Mehta, Managing Director and Promoter of Kilitch Drugs (India) Limited, has submitted a disclosure under SEBI's substantial acquisition regulations. The filing confirms that the promoters and persons acting in concert (PACs) have NOT created any encumbrance (pledge, mortgage, or charge) over their shares during the financial year ended 31st March 2026. This is a routine annual compliance filing required under Regulation 31(4) of SEBI SAST Regulations, 2011. The disclosure was submitted to both BSE (Scrip Code: 524500) and NSE (Scrip Code: KILITCH).

Likely market impact

This is a positive indicator for minority shareholders as it shows promoters have not pledged their shares, meaning no risk of forced selling from promoter collateral. It reflects healthy promoter commitment to the company without leveraging their shareholding position.